Annual Total Liabilities
$972.49 M
+$127.89 M+15.14%
December 31, 2023
Summary
- As of February 25, 2025, BCRX annual total liabilities is $972.49 million, with the most recent change of +$127.89 million (+15.14%) on December 31, 2023.
- During the last 3 years, BCRX annual total liabilities has risen by +$618.51 million (+174.73%).
- BCRX annual total liabilities is now at all-time high.
Performance
BCRX Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$959.82 M
+$11.79 M+1.24%
September 30, 2024
Summary
- As of February 25, 2025, BCRX quarterly total liabilities is $959.82 million, with the most recent change of +$11.79 million (+1.24%) on September 30, 2024.
- Over the past year, BCRX quarterly total liabilities has stayed the same.
- BCRX quarterly total liabilities is now -1.30% below its all-time high of $972.49 million, reached on December 31, 2023.
Performance
BCRX Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
BCRX Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +15.1% | 0.0% |
| 3 y3 years | +174.7% | +132.5% |
| 5 y5 years | +896.3% | +628.5% |
BCRX Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +39.9% | -1.3% | +38.7% |
| 5 y | 5-year | at high | +609.7% | -1.3% | +622.0% |
| alltime | all time | at high | >+9999.0% | -1.3% | >+9999.0% |
BioCryst Pharmaceuticals Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $959.82 M(+1.2%) |
| Jun 2024 | - | $948.02 M(+0.4%) |
| Mar 2024 | - | $944.06 M(-2.9%) |
| Dec 2023 | $972.49 M(+15.1%) | $972.49 M(+4.1%) |
| Sep 2023 | - | $933.91 M(+1.7%) |
| Jun 2023 | - | $918.60 M(+9.6%) |
| Mar 2023 | - | $838.02 M(-0.8%) |
| Dec 2022 | $844.60 M(+21.5%) | $844.60 M(+5.4%) |
| Sep 2022 | - | $801.25 M(+10.7%) |
| Jun 2022 | - | $723.77 M(+4.6%) |
| Mar 2022 | - | $691.93 M(-0.5%) |
| Dec 2021 | $695.14 M(+96.4%) | $695.14 M(+68.4%) |
| Sep 2021 | - | $412.81 M(+7.7%) |
| Jun 2021 | - | $383.36 M(+6.7%) |
| Mar 2021 | - | $359.42 M(+1.5%) |
| Dec 2020 | $353.98 M(+158.3%) | $353.98 M(+148.2%) |
| Sep 2020 | - | $142.59 M(+3.2%) |
| Jun 2020 | - | $138.20 M(+4.0%) |
| Mar 2020 | - | $132.94 M(-3.0%) |
| Dec 2019 | $137.03 M(+40.4%) | $137.03 M(+4.0%) |
| Sep 2019 | - | $131.75 M(+5.0%) |
| Jun 2019 | - | $125.54 M(+4.8%) |
| Mar 2019 | - | $119.83 M(+22.8%) |
| Dec 2018 | $97.61 M(+3.3%) | $97.61 M(+2.3%) |
| Sep 2018 | - | $95.44 M(+5.5%) |
| Jun 2018 | - | $90.46 M(-3.1%) |
| Mar 2018 | - | $93.32 M(-1.2%) |
| Dec 2017 | $94.49 M(+7.1%) | $94.49 M(+4.0%) |
| Sep 2017 | - | $90.86 M(+1.6%) |
| Jun 2017 | - | $89.43 M(-1.7%) |
| Mar 2017 | - | $90.98 M(+3.1%) |
| Dec 2016 | $88.27 M(+18.3%) | $88.27 M(+0.9%) |
| Sep 2016 | - | $87.51 M(+27.1%) |
| Jun 2016 | - | $68.83 M(-8.3%) |
| Mar 2016 | - | $75.08 M(+0.6%) |
| Dec 2015 | $74.64 M(+21.9%) | $74.64 M(-0.4%) |
| Sep 2015 | - | $74.91 M(+1.1%) |
| Jun 2015 | - | $74.09 M(+13.1%) |
| Mar 2015 | - | $65.50 M(+7.0%) |
| Dec 2014 | $61.24 M(+22.5%) | $61.24 M(+14.1%) |
| Sep 2014 | - | $53.67 M(+3.4%) |
| Jun 2014 | - | $51.89 M(+5.7%) |
| Mar 2014 | - | $49.11 M(-1.8%) |
| Dec 2013 | $49.99 M(-13.6%) | $49.99 M(+0.4%) |
| Sep 2013 | - | $49.80 M(+1.7%) |
| Jun 2013 | - | $48.96 M(-1.6%) |
| Mar 2013 | - | $49.74 M(-14.1%) |
| Dec 2012 | $57.89 M(-14.1%) | $57.89 M(+6.6%) |
| Sep 2012 | - | $54.31 M(-10.3%) |
| Jun 2012 | - | $60.58 M(+6.4%) |
| Mar 2012 | - | $56.94 M(-15.5%) |
| Dec 2011 | $67.40 M(+53.4%) | $67.40 M(+1.4%) |
| Sep 2011 | - | $66.47 M(-3.9%) |
| Jun 2011 | - | $69.15 M(+0.8%) |
| Mar 2011 | - | $68.60 M(+56.1%) |
| Dec 2010 | $43.94 M(-21.4%) | $43.94 M(+18.8%) |
| Sep 2010 | - | $37.01 M(+13.9%) |
| Jun 2010 | - | $32.49 M(-17.0%) |
| Mar 2010 | - | $39.13 M(-30.0%) |
| Dec 2009 | $55.92 M | $55.92 M(+51.0%) |
| Sep 2009 | - | $37.04 M(+10.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2009 | - | $33.41 M(-2.0%) |
| Mar 2009 | - | $34.09 M(-10.9%) |
| Dec 2008 | $38.27 M(-50.8%) | $38.27 M(-40.5%) |
| Sep 2008 | - | $64.34 M(-1.4%) |
| Jun 2008 | - | $65.23 M(-12.9%) |
| Mar 2008 | - | $74.92 M(-3.7%) |
| Dec 2007 | $77.81 M(+64.4%) | $77.81 M(+3.0%) |
| Sep 2007 | - | $75.55 M(+9.4%) |
| Jun 2007 | - | $69.08 M(+28.1%) |
| Mar 2007 | - | $53.92 M(+13.9%) |
| Dec 2006 | $47.33 M(+16.0%) | $47.33 M(-5.7%) |
| Sep 2006 | - | $50.18 M(+5.7%) |
| Jun 2006 | - | $47.49 M(-3.1%) |
| Mar 2006 | - | $49.00 M(+20.1%) |
| Dec 2005 | $40.81 M(+1201.9%) | $40.81 M(+989.1%) |
| Sep 2005 | - | $3.75 M(+46.3%) |
| Jun 2005 | - | $2.56 M(-14.1%) |
| Mar 2005 | - | $2.98 M(-4.8%) |
| Dec 2004 | $3.13 M(+90.1%) | $3.13 M(-12.2%) |
| Sep 2004 | - | $3.57 M(+51.3%) |
| Jun 2004 | - | $2.36 M(-6.6%) |
| Mar 2004 | - | $2.52 M(+53.2%) |
| Dec 2003 | $1.65 M(+40.6%) | $1.65 M(+15.2%) |
| Sep 2003 | - | $1.43 M(-9.7%) |
| Jun 2003 | - | $1.58 M(+33.5%) |
| Mar 2003 | - | $1.19 M(+1.3%) |
| Dec 2002 | $1.17 M(-48.7%) | $1.17 M(-5.0%) |
| Sep 2002 | - | $1.23 M(-25.9%) |
| Jun 2002 | - | $1.67 M(-9.3%) |
| Mar 2002 | - | $1.83 M(-19.6%) |
| Dec 2001 | $2.28 M(-75.6%) | $2.28 M(+107.5%) |
| Sep 2001 | - | $1.10 M(-75.0%) |
| Jun 2001 | - | $4.40 M(-44.4%) |
| Mar 2001 | - | $7.92 M(-15.3%) |
| Dec 2000 | $9.35 M(+367.3%) | $9.35 M(+658.6%) |
| Sep 2000 | - | $1.23 M(-32.4%) |
| Jun 2000 | - | $1.82 M(+13.5%) |
| Mar 2000 | - | $1.61 M(-19.7%) |
| Dec 1999 | $2.00 M(+42.9%) | $2.00 M(+33.3%) |
| Sep 1999 | - | $1.50 M(+15.4%) |
| Jun 1999 | - | $1.30 M(0.0%) |
| Mar 1999 | - | $1.30 M(-7.1%) |
| Dec 1998 | $1.40 M(+16.7%) | $1.40 M(-22.2%) |
| Sep 1998 | - | $1.80 M(+20.0%) |
| Jun 1998 | - | $1.50 M(-11.8%) |
| Mar 1998 | - | $1.70 M(+41.7%) |
| Dec 1997 | $1.20 M(-29.4%) | $1.20 M(-25.0%) |
| Sep 1997 | - | $1.60 M(-11.1%) |
| Jun 1997 | - | $1.80 M(+5.9%) |
| Mar 1997 | - | $1.70 M(0.0%) |
| Dec 1996 | $1.70 M(-5.6%) | $1.70 M(+6.3%) |
| Sep 1996 | - | $1.60 M(-15.8%) |
| Jun 1996 | - | $1.90 M(+18.8%) |
| Mar 1996 | - | $1.60 M(-11.1%) |
| Dec 1995 | $1.80 M(+12.5%) | $1.80 M(+38.5%) |
| Sep 1995 | - | $1.30 M(-18.8%) |
| Jun 1995 | - | $1.60 M(+14.3%) |
| Mar 1995 | - | $1.40 M(-12.5%) |
| Dec 1994 | $1.60 M | $1.60 M(-5.9%) |
| Sep 1994 | - | $1.70 M(-26.1%) |
| Jun 1994 | - | $2.30 M(-8.0%) |
| Mar 1994 | - | $2.50 M |
FAQ
- What is BioCryst Pharmaceuticals annual total liabilities?
- What is the all time high annual total liabilities for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals annual total liabilities year-on-year change?
- What is BioCryst Pharmaceuticals quarterly total liabilities?
- What is the all time high quarterly total liabilities for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals quarterly total liabilities year-on-year change?
What is BioCryst Pharmaceuticals annual total liabilities?
The current annual total liabilities of BCRX is $972.49 M
What is the all time high annual total liabilities for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high annual total liabilities is $972.49 M
What is BioCryst Pharmaceuticals annual total liabilities year-on-year change?
Over the past year, BCRX annual total liabilities has changed by +$127.89 M (+15.14%)
What is BioCryst Pharmaceuticals quarterly total liabilities?
The current quarterly total liabilities of BCRX is $959.82 M
What is the all time high quarterly total liabilities for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high quarterly total liabilities is $972.49 M
What is BioCryst Pharmaceuticals quarterly total liabilities year-on-year change?
Over the past year, BCRX quarterly total liabilities has changed by $0.00 (0.00%)